Our strategic planning of therapeutic areas for development of new and generic drugs, as well as cellular products is based on the in-depth analysis of the patient population needs in the Russian Federation for various medical products and treatments. Currently, we are pursuing research and development of therapies for the following diseases and pathological conditions.

The abnormal growth of blood vessels, stimulated by VEGF, is one of the pathogenetic mechanisms of retinal damage and vision loss in such common diseases as age-related macular degeneration and diabetic retinopathy. Ranibizumab, which is a modified form of Bevacizumab, was successfully used for treatment of the wet (exudative) form of age-related macular degeneration and macular oedema due to retinal vein occlusion.